PMID- 33297189 OWN - NLM STAT- MEDLINE DCOM- 20201221 LR - 20201221 IS - 1879-1298 (Electronic) IS - 0045-6535 (Linking) VI - 263 DP - 2021 Jan TI - Functional benefit and molecular mechanism of vitamin C against perfluorooctanesulfonate-associated leukemia. PG - 128242 LID - S0045-6535(20)32437-1 [pii] LID - 10.1016/j.chemosphere.2020.128242 [doi] AB - Perfluorooctanesulfonate (PFOS) is a persistent pollutant that can induce toxic effects, including leukemia, on blood cells. Vitamin C (VC), a functional nutrient, has been found to possess potent cytoprotective effects. However, there are currently no reports on its ability to treat PFOS-associated leukemia. This study used a molecular networking analysis to reveal the functional action and pharmacological mechanism of VC against PFOS-associated leukemia. The biological informatics findings revealed a total of 17 intersection targets against PFOS-associated leukemia. In addition, seven core-functional targets, including tumor protein p53 (TP53), mitogen-activated protein kinase 1 (MAPK1), estrogen receptor 1 (ESR1), sirtuin 1 (SIRT1), nitric oxide synthase 3 (NOS3), myeloid cell leukemia-1 (MCL1), and telomerase reverse transcriptase (TERT), were screened and identified. Notably, the molecular docking findings indicated that TP53, MAPK1, and ESR1 were potent pharmacological targets of VC against PFOS-associated leukemia. Moreover, the pharmacological functions including biological processes, cell components, and molecular pathways of VC against PFOS-associated leukemia were determined. According to the computational findings, we conclude that VC protects against PFOS-associated leukemia action by suppressing leukemia-associated cell proliferation and tumor growth. The validated genes of TP53, MAPK1, ESR1 may become potential biomarkers for monitoring and treating PFOS-associated leukemia. CI - Copyright (c) 2020 Elsevier Ltd. All rights reserved. FAU - Li, Rong AU - Li R AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China. FAU - Guo, Chao AU - Guo C AD - Department of Pharmacy, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, Guangxi, PR China. FAU - Li, Yu AU - Li Y AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China. FAU - Liang, Xiao AU - Liang X AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China. FAU - Su, Min AU - Su M AD - Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China. Electronic address: college_sumin@126.com. LA - eng PT - Journal Article DEP - 20200904 PL - England TA - Chemosphere JT - Chemosphere JID - 0320657 RN - 0 (Alkanesulfonic Acids) RN - 0 (Fluorocarbons) RN - 9H2MAI21CL (perfluorooctane sulfonic acid) RN - PQ6CK8PD0R (Ascorbic Acid) SB - IM MH - *Alkanesulfonic Acids/toxicity MH - Ascorbic Acid MH - *Fluorocarbons/toxicity MH - Humans MH - *Leukemia/chemically induced MH - Molecular Docking Simulation MH - Signal Transduction OTO - NOTNLM OT - Leukemia OT - Molecular mechanism OT - Network pharmacology OT - Perfluorooctanesulfonate OT - Pharmacological targets OT - Vitamin C COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2020/12/11 06:00 MHDA- 2020/12/22 06:00 CRDT- 2020/12/10 01:02 PHST- 2020/07/02 00:00 [received] PHST- 2020/08/27 00:00 [revised] PHST- 2020/08/31 00:00 [accepted] PHST- 2020/12/10 01:02 [entrez] PHST- 2020/12/11 06:00 [pubmed] PHST- 2020/12/22 06:00 [medline] AID - S0045-6535(20)32437-1 [pii] AID - 10.1016/j.chemosphere.2020.128242 [doi] PST - ppublish SO - Chemosphere. 2021 Jan;263:128242. doi: 10.1016/j.chemosphere.2020.128242. Epub 2020 Sep 4.